Related references
Note: Only part of the references are listed.A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
Outi Kilpivaara et al.
NATURE GENETICS (2009)
Signals that maintain leukemic cell viability
Janet Plate
BLOOD (2008)
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia
Marc M. Loriaux et al.
BLOOD (2008)
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
Michael H. Tomasson et al.
BLOOD (2008)
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Timothy J. Ley et al.
NATURE (2008)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
Linda M. Scott et al.
BLOOD (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
RL Levine et al.
BLOOD (2005)
Genetics of myeloid malignancies:: Pathogenetic and clinical implications
S Fröhling et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Identification of an acquired JAK2 mutation in Polycythemia vera
RX Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes
TJ Ley et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)